grant
Targeting the cytokine circuitry of KRAS driven lung cancer
Organization DANA-FARBER CANCER INSTLocation BOSTON, UNITED STATESPosted 1 Apr 2015Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY20263 Prime Repair Exonuclease 13 Prime Repair Exonuclease 1 GeneATR-Interacting ProteinATR-Interacting Protein GeneATRIPATRIP GeneActive Follow-upAnti-viral ResponseAntioncogene Protein p53Biologic ModelsBiological ModelsC-K-RASCancer GenesCancer-Promoting GeneCancersCell BodyCell Communication and SignalingCell SignalingCell SurvivalCell ViabilityCell-Mediated CytolysisCell-Mediated LympholysisCellsCellular CytotoxicityCellular Tumor Antigen P53Chemotactic CytokinesClinical TrialsColorectal CancerCyclicityCytokine Signal TransductionCytokine SignalingCytotoxic cellDKFZp434J0310DKFZp434J0310 GeneDNADNA ExonucleasesDNA mutationDNase III GeneDRN3DRN3 GeneDataDeoxyribonuclease III, DnaQ/MutD (E. coli)-LikeDeoxyribonuclease III, DnaQ/MutD (E. coli)-Like GeneDeoxyribonucleic AcidDependenceDetectable Residual DiseaseDevelopmentDiseaseDisorderDouble-Stranded DNADrug ToleranceDrugsEffector CellEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessExposure toFLJ11330FLJ12343FLJ12343 GeneFOSL1FOSL1 geneFRA1FaceFeedbackFos-Like Antigen 1 GeneFutureGEM modelGEMM modelGene InactivationGene SilencingGeneticGenetic ChangeGenetic defectGenetic mutationGenetically Engineered MouseGoalsHomologous Chemotactic CytokinesHumanIFNIFN-GammaIFN-gIFN-regulatory factor 3IFN-γIFNGIFNγIRF-3 proteinIRF3IRF3 geneImmuneImmune InterferonImmune mediated therapyImmune signalingImmune systemImmunesImmunocompetentImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIn VitroInflammatoryIntercrinesInterferon GammaInterferon Regulatory Factor 3Interferon Type IIInterferonsIntracellular Communication and SignalingIntratumoral heterogeneityK lymphocyteK-RAS2AK-RAS2BK-RasK-Ras 2AK-Ras-2 OncogeneKRASKRAS driven oncogenesisKRAS oncogenesisKRAS(G12D)KRAS-driven tumorigenesisKRAS-mediated tumorigenesisKRAS2KRAS2 geneKRASG12DKi-RASLKB1LKB1/STK11 GeneLaboratoriesLung NeoplasmsLung TumorLymphocyte CytotoxicityLymphocytotoxicityMalignant CellMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungManuscriptsMediatingMedicationMiceMice MammalsMinimal Residual DiseaseModel SystemModelingModern ManMurineMusMutateMutationNF-Kb-Activating Kinase GeneNK CellsNSCLCNSCLC - Non-Small Cell Lung CancerNatural Killer CellsNatureNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaOncogene K-RasOncogenesOncoprotein p53OutputP53PD-1 blockadePD1 blockadePancreas Ductal AdenocarcinomaPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPeriodicityPharmaceutical PreparationsPhosphoprotein P53Phosphoprotein pp53PhysiologicPhysiologicalPopulationProtein TP53PublishingPulmonary CancerPulmonary NeoplasmsPulmonary malignant NeoplasmRASK2RNA SeqRNA sequencingRNAseqRefractoryRegulationResearchResidual NeoplasmResidual TumorsResistanceRhythmicitySIS cytokinesSTAT1STAT1 geneSTAT91STK11STK11 geneSeriesSignal PathwaySignal TransductionSignal Transduction SystemsSignalingStimulator of Interferon GenesT-CellsT-LymphocyteT2KTBK1TBK1 geneTP53TP53 geneTREX1TREX1 geneTRP53TestingTherapeuticThree Prime Repair Exonuclease 1Three Prime Repair Exonuclease 1 GeneTransforming GenesTranslationsTrex1 3'-5' exonucleaseTrex1 exonucleaseTumor BiologyTumor CellTumor Protein p53Tumor Protein p53 GeneTumor Suppressor ProteinsTumorigenicityVascularizationViralWorkactive followupadvanced diseaseadvanced illnessanti-PD-1 blockadeanti-PD1 blockadebiological signal transductioncGAMP STINGcGAMP-STINGcGAMP/STINGcGAS/STINGcancer cellcancer microenvironmentcancer typecell killingcell mediated cytotoxicitycell typecheck point blockadecheckpoint blockadechemoattractant cytokinechemokinecyclic GMP-AMP synthase/STINGcytokinedevelopmentaldrug/agentds-DNAdsDNAepigenetic gene silencingepigenetic silencingepigeneticallyexodeoxyribonucleasefacesfacialfollow upfollow-upfollowed upfollowupgenetically engineered mouse modelgenetically engineered murine modelgenome mutationheterogeneity in tumorsimmune check point blockadeimmune checkpoint blockadeimmune competentimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenicimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentin vivoinhibitorinnate check pointinnate checkpointinnate immune check pointinnate immune checkpointinnate immunity checkpointinnovateinnovationinnovativeintra-tumoral heterogeneityintratumor heterogeneitylFN-Gammaliver kinase B1lung cancerlung cancer cellmalignancymicronucleusmicrophysiologic modelmicrophysiologic platformmicrophysiologic systemmicrophysiology modelmicrophysiology platformmicrophysiology systemmouse modelmurine modelmutantneoplasm/cancerneoplastic cellnew approachesnovelnovel approachesnovel strategiesnovel strategyoncogenic KRASp53 Antigenp53 Genesp53 Tumor Suppressorpathwaypharmacologicprogramsprotein p53recruitresidual diseaseresistantresponserestraintscRNA sequencingscRNA-seqsensorsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsmall moleculespheroidstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentthymus derived lymphocytetraffickingtranscriptional silencingtranscriptome sequencingtranscriptomic sequencingtranslationtranslational opportunitiestranslational potentialtumortumor heterogeneitytumor immune microenvironmenttumor microenvironmenttumor suppressortumor-immune system interactionsv-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY
Despite recent major advances in immunotherapy and targeted therapy for KRAS mutant lung cancer, durable
responses remain rare, and the vast majority of patients succumb to advanced disease. My laboratory has
pursued a unique angle to the study of this disease, centered around innate immune signaling. We have identified…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click